Shots:

• Under the agreement, the companies will jointly invest the funds & will be responsible to develop & validate the personalized solid tumor MRD assays for cancer monitoring & recurrence in China
• The agreement will combine AstraZeneca’s oncology drug development, invaluable insights, diagnostic platform & lab expertise with Genetron’s expertise to develop MRD products, based on
• AstraZeneca plans to include the co-developed tests for further studies in China. Genetron’s MRD program is designed by its mutation capsule technology which is used for the development of liquid biopsy assays

/ article | Ref: Globe Newswire | Image: Genetron Health